title: Neuroimaging and treatment evidence for clinical staging in psychotic disorders: from the at-risk mental state to chronic schizophrenia.
abstract: A new approach to understanding severe mental disorders such as schizophrenia is to adopt a clinical staging model. Such a model defines the extent of the illness such that earlier and milder phenomena are distinguished from later, more impairing features. Specifically, a clinical staging model makes three key predictions. First, pathologic measures should be more abnormal in more severe stages. Second, patients who progress between the stages should show change in these same pathologic measures. Finally, treatment should be more effective in the earlier stages, as well as more benign. In this article, we review the evidence for these three predictions from studies of psychotic disorders, with a focus on neuroimaging data. For all three, the balance of evidence supports the predictions of the staging model. However, there are a number of alternative explanations for these findings, including the effects of medication and symptom heterogeneity.
authors.affiliation: Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Melbourne, Australia. s.j.wood@bham.ac.uk
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Wood
authors.forename: Alison R
authors.initials: AR
authors.lastname: Yung
authors.forename: Patrick D
authors.initials: PD
authors.lastname: McGorry
authors.forename: Christos
authors.initials: C
authors.lastname: Pantelis
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000473:pathology; D018450:Disease Progression; D006801:Humans; D059906:Neuroimaging / Q000523:psychology*; D011618:Psychotic Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D012559:Schizophrenia / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology
chemical_list: D014150:Antipsychotic Agents